Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note issued to investors on Friday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Stock Down 0.5 %

Shares of NYSE BTX opened at $6.43 on Friday. The business’s 50 day moving average is $2.50 and its two-hundred day moving average is $1.48. Brooklyn ImmunoTherapeutics has a 52-week low of $6.35 and a 52-week high of $8.31. The firm has a market cap of $378.25 million, a price-to-earnings ratio of -2.83 and a beta of 4.61.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.